Norethindrone

• Description:

  Norethindrone is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea.

• Product Name Alternative:

  Norethisterone

• UNSPSC:

  12352211

• Hazard Statement:

  H302, H351, H360, H410

• Target:

  Bacterial; Progesterone Receptor

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Vitamin D Related/Nuclear Receptor

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Endocrinology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/norethindrone.html

• Purity:

  99.37

• Solubility:

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 2.7 mg/mL (ultrasonic)

• Smiles:

  C[C@@]1([C@]2(O)C#C)[C@](CC2)([H])[C@@](CCC3=CC4=O)([H])[C@]([C@@]3([H])CC4)([H])CC1

• Molecular Formula:

  C20H26O2

• Molecular Weight:

  298.42

• Precautions:

  H302, H351, H360, H410

• References & Citations:

  [1]Muneyyirci-Delale O, et al. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998 Jan-Feb;43 (1) :24-7.|[2]Kaser DJ, et al. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol. 2012 Apr;25 (2) :105-8.|[3]Maier WE, et al. Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals. Regul Toxicol Pharmacol. 2001 Aug;34 (1) :53-61.|[4]Cheng DC, et al. Norethindrone acetate inhibition of triglyceride synthesis and release by rat hepatocytes. Atherosclerosis. 1983 Jan;46 (1) :41-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [68-22-4]